Sale

Radiopharmaceuticals Market

Global Radiopharmaceuticals Market Size, Share, Trends, Value, Growth, Forecast: By Product Type: Diagnostic Nuclear Medicine, PET Radiopharmaceuticals, Therapeutic Nuclear Medicine, Brachytherapy Isotopes, Beta Emitters; By Applications; By Volume Assessment; By Source; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Global Radiopharmaceuticals Market Outlook

The global radiopharmaceuticals market value was USD 5.38 billion in 2023, driven by the increasing prevalence of chronic diseases across the globe. The market value is anticipated to grow at a CAGR of 7.5% during the forecast period of 2024-2032 to achieve a value of USD 10.31 billion by 2032.

 

Global Radiopharmaceuticals Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

North America Market to Continue Dominating the Overall Market Over the Forecast Period

Owing to the presence of prominent pharmaceutical key players and well-funded research facilities, the North America region is estimated to maintain its dominance over the market share for radiopharmaceuticals. Meanwhile, the steady growth of the industry in leading Asia Pacific countries make a worthwhile contribution to the rising regional industry, which is projected to witness the fastest growth in the coming years. The SPECT segment, among the diagnostic radiopharmaceuticals, is extensively utilised in the maintenance of thyroid-related medical issues. Attributing to the commonality of these issues, the thyroid applications of radiopharmaceuticals is likely to witness robust growth during the forecast period. Moreover, under the therapeutic segment, oncology applications are estimated to grow in the coming years owing to a continual rise in the number of cancer cases. Although, due to the higher presence of alternatives in the therapeutic segment, the diagnostic pharmaceuticals are projected to achieve higher growth.

 

Radiopharmaceuticals: Market Segmentation

A radiopharmaceutical, also known as a medicinal radio compound, is a pharmaceutical drug containing radioisotopes that can be used as a diagnosis medication, as well as a therapeutic agent. Radiopharmaceuticals can be used for both chronic and critical diseases and are widely used in molecular imaging as biomarkers.

 

Global Radiopharmaceuticals Market by Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

By generators type, the market is segmented into:

  • W-188/Re-188 Generators
  • Mo-99/Tc-99m Generators
  • Sr-82/Rb-82 Generators
  • Sr-90/Y-90 Generators
  • Ge-68/Ga-67,68 Generators

Based on application, the industry can be divided into:

  • Diagnostic Radiopharmaceuticals
    • SPECT (Single-Photon Emission Computed Tomography)
    • PET (Positron Emission Tomography)
  • Therapeutic Radiopharmaceuticals
    • Oncology
    • Cardiology and Neurology
  • Theranostics

The end uses for radiopharmaceuticals include:

  • Hospitals
  • Diagnostic Centres

The EMR report looks into the regional markets of radiopharmaceuticals like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Global Radiopharmaceuticals Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Higher Prevalence of Chronic Diseases Likely to Bolster the Market Growth for Radiopharmaceuticals

The radiopharmaceuticals sector is the fastest-growing segment in the pharmaceutical industry. The global market of radiopharmaceuticals is primarily propelled by the worldwide need for timely diagnostics and treatment of fatal diseases. Unhealthy lifestyles of people all over the world has resulted in a higher prevalence of chronic diseases in recent years, and subsequently, the revolutionary utilisation of radiopharmaceuticals in diagnostics is gaining popularity in the healthcare sector.

Moreover, rising acceptance of disease specific therapy, enhanced patient awareness regarding accurate and timely diagnosis, and expanding applications of molecular imaging are some other factors providing a boost to the market growth for radiopharmaceuticals. Meanwhile, various factors including supply volatility and competition from conventional diagnostic procedures, are likely to impede the market growth. Nevertheless, constant growth in the research and development sector, and high capital investment are estimated to counter any such hurdles.

 

Key Industry Players in the Global Radiopharmaceuticals Market

The report presents a detailed analysis of the following key players in the global radiopharmaceuticals market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Jubilant Pharma Holdings Inc.
  • Clarity Pharmaceutical
  • Cardinal Health
  • Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product Type
  • Applications
  • Volume Assessment
  • Source
  • End User
  • Region
Breakup by Product Type
  • Diagnostic Nuclear Medicine
  • PET Radiopharmaceuticals
  • Therapeutic Nuclear Medicine
  • Brachytherapy Isotopes
  • Beta Emitters
Breakup by Applications
  • SPECT Applications
  • PET applications
  • Therapeutic Applications
Breakup by Volume Assessment
  • Diagnostic Procedures
  • Therapeutic Procedures
Breakup by Source
  • Nuclear Rectors
  • Cyclotrons
Breakup by End User
  • Hospitals
  • Ambulatory Surgical Centres
  • Diagnostic Centres
  • Cancer Research Institutes
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Cardinal Health
  • GE Healthcare
  • Lantheus Medical Imaging
  • Bayer AG
  • Bracco Imaging
  • Nordion
  • NTP Radioisotopes
  • NorthStar Medical Radioisotopes
  • Eckert & Ziegler
  • Braun Melsungen AG
  • Smith Nephew
  • Zimmer Biomet
  • Hanger Inc.
  • Otto Bock Healthcare

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Radiopharmaceuticals Market Overview 

    3.1    Global Radiopharmaceuticals Market Historical Value (2017-2023) 
    3.2    Global Radiopharmaceuticals Market Forecast Value (2024-2032)
4    Global Radiopharmaceuticals Market Landscape
    4.1    Global Radiopharmaceuticals Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Radiopharmaceuticals Product Landscape
        4.2.1    Analysis by Product Type
        4.2.2    Analysis by End User
        4.2.3    Analysis by Applications
5    Global Radiopharmaceuticals Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Radiopharmaceuticals Market Segmentation
    6.1    Global Radiopharmaceuticals Market, by Product Type
        6.1.1     Market Overview
            6.1.1.1    Diagnostic Nuclear Medicine
                6.1.1.1.1    SPECT Radiopharmaceuticals
                6.1.1.1.2    Technetium-99m
                6.1.1.1.3    Thallium-201
                6.1.1.1.4    Gallium-67
                6.1.1.1.5    Iodine-123
                6.1.1.1.6    Other
            6.1.1.2    PET Radiopharmaceuticals
                6.1.1.2.1    F-18
                6.1.1.2.2    RU-82
                6.1.1.2.3    Others
            6.1.1.3    Therapeutic Nuclear Medicine
                6.1.1.3.1    Alpha Emitters
                6.1.1.3.2    Ra-223
            6.1.1.4    Brachytherapy Isotopes
                6.1.1.4.1    Intoiodine-125
                6.1.1.4.2    Palladium-103
                6.1.1.4.3    Cesium-131
                6.1.1.4.4    Iridium-192
                6.1.1.4.5    Other brachytherapy isotopes
            6.1.1.5    Beta Emitters
                6.1.1.5.1    Intoiodine-131
                6.1.1.5.2    Yttrium-90
                6.1.1.5.3    Samarium-153
                6.1.1.5.4    Lutetium-177
                6.1.1.5.5    Rhenium-186
                6.1.1.5.6    Other beta emitters
    6.2    Global Radiopharmaceuticals Market, by Applications
        6.2.1    Market Overview    
        6.2.2    Diagnostic Applications
        6.2.3    SPECT Applications
            6.2.3.1    Cardiology
            6.2.3.2    Bone Scans
            6.2.3.3    Thyroid Applications
            6.2.3.4    Pulmonary Scans
            6.2.3.5    Other SPECT Applications
        6.2.4    PET applications
            6.2.4.1    Oncology
            6.2.4.2    Cardiology
            6.2.4.3    Neurology
            6.2.4.4    Other PET applications
        6.2.5    Therapeutic Applications
            6.2.5.1    Thyroid Indications
            6.2.5.2    Bone Metastasis
            6.2.5.3    Lymphoma
            6.2.5.4    Endocrine Tumors
            6.2.5.5    Other Indications
    6.3    Global Radiopharmaceuticals Market, by Volume Assessment 
        6.3.1    Market Overview
        6.3.2    Diagnostic Procedures
        6.3.3    Therapeutic Procedures
    6.4    Global Radiopharmaceuticals Market, by Source
        6.4.1    Market Overview
        6.4.2    Nuclear Rectors
        6.4.3    Cyclotrons
    6.5    Global Radiopharmaceuticals Market, by End User
        6.5.1    Market Overview
        6.5.2    Hospitals
        6.5.3    Ambulatory Surgical Centres
        6.5.4    Diagnostic Centres
        6.5.5    Cancer Research Institutes
        6.5.6    Others
    6.6    Global Radiopharmaceuticals Market by Region
        6.6.1    Market Overview
        6.6.2    North America 
        6.6.3    Europe
        6.6.4    Asia Pacific
        6.6.5    Latin America
        6.6.6    Middle East and Africa
7    North America Radiopharmaceuticals Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Radiopharmaceuticals Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Radiopharmaceuticals Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Radiopharmaceuticals Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Radiopharmaceuticals Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Funding Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Supplier Landscape
    17.1    Cardinal Health
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3     Demographic Reach and Achievements
        17.1.4     Mergers and Acquisitions
        17.1.5     Certifications
    17.2    GE Healthcare
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3     Demographic Reach and Achievements
        17.2.4     Mergers and Acquisitions
        17.2.5     Certifications
    17.3    Lantheus Medical Imaging
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3     Demographic Reach and Achievements
        17.3.4     Mergers and Acquisitions
        17.3.5     Certifications
    17.4    Bayer AG
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3     Demographic Reach and Achievements
        17.4.4     Mergers and Acquisitions
        17.4.5     Certifications
    17.5    Bracco Imaging
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3     Demographic Reach and Achievements
        17.5.4     Mergers and Acquisitions
        17.5.5     Certifications
    17.6    Nordion
        17.6.1    Financial Analysis
        17.6.2     Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4     Mergers and Acquisitions
        17.6.5     Certifications
    17.7    NTP Radioisotopes
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3     Demographic Reach and Achievements
        17.7.4     Mergers and Acquisitions
        17.7.5     Certifications
    17.8    NorthStar Medical Radioisotopes
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4     Mergers and Acquisitions
        17.8.5     Certifications
    17.9    Eckert & Ziegler
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4     Mergers and Acquisitions
        17.9.5     Certifications
    17.10    Braun Melsungen AG
        17.10.1     Financial Analysis
        17.10.2     Product Portfolio
        17.10.3     Demographic Reach and Achievements
        17.10.4     Mergers and Acquisitions
        17.10.5     Certifications
    17.11    Smith Nephew
        17.11.1     Financial Analysis
        17.11.2     Product Portfolio
        17.11.3     Demographic Reach and Achievements
        17.11.4     Mergers and Acquisitions
        17.11.5     Certifications
    17.12    Zimmer Biomet
        17.12.1     Financial Analysis
        17.12.2     Product Portfolio
        17.12.3     Demographic Reach and Achievements
        17.12.4     Mergers and Acquisitions
        17.12.5     Certifications
    17.13    Hanger Inc.
        17.13.1     Financial Analysis
        17.13.2     Product Portfolio
        17.13.3     Demographic Reach and Achievements
        17.13.4     Mergers and Acquisitions
        17.13.5     Certifications
    17.14     Otto Bock Healthcare
        17.14.1     Financial Analysis
        17.14.2     Product Portfolio
        17.14.3     Demographic Reach and Achievements
        17.14.4     Mergers and Acquisitions
        17.14.5     Certifications
18    Global Radiopharmaceuticals Market-Distribution Model (Additional Insight)
    18.1    Overview
    18.2    Potential Distributors
    18.3    Key Parameters for Distribution Partner Assessment
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Pricing Models and Strategies (Additional Insight)
    21.1    Overview
    21.2    Cost Model
        21.2.1    Manufacturing Cost Analysis
        21.2.2    Procurement Cost Analysis
        21.2.3    Clinical Trial Cost Factors
    21.3    Pricing Strategies
        21.3.1     Competitor Pricing Analysis
        21.3.2     Key Assessment of Product Attributes
        21.3.3     Pricing Benchmark

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The radiopharmaceuticals Market was valued at USD 5.38 billion in 2023.

The market is expected to grow at a CAGR of 7.5% from 2024 to 2032 to reach a value of USD 10.31 billion by 2032.

The deployment of radiopharmaceuticals in SPECT diagnosis owing to the commonality of thyroid, and the oncology segment of therapeutics is driving the market growth.

The rising prevalence of radiopharmaceuticals to effectively diagnose and treat chronic diseases caused by unhealthy lifestyle is expected to propel the market growth of radiopharmaceuticals.

The major regional markets for radiopharmaceuticals are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.

The different types of generators used in the radiopharmaceutical industry are W-188/Re-188 generators, Mo-99/Tc-99m generators, Sr-82/Rb-82 generators, Sr-90/Y-90 generators, and Ge-68/Ga-67,68 generators.

The significant applications of radiopharmaceuticals are diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals, and theranostics.

The major end use sectors of the radiopharmaceutical industry are hospitals, and diagnostic centres.

The major players in the industry are Jubilant Pharma Holdings Inc., Clarity Pharmaceuticals, and Cardinal Health, among others.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER